About Stage Two COPD

Chronic obstructive pulmonary disease  (COPD) is a progressive disease that typically increases in severity over time. Stage Two COPD is an early stage in the disease’s progression. This stage is also called moderate COPD.

Lung Capacity in Stage Two COPD

A major sign that a person has COPD is the capacity of his or her lungs is decreased. Due to constant inflammation of the airways, COPD patients struggle to breathe properly. They have difficulty blowing out air with any force, and the overall volume of air they can hold in their lungs is diminished. The forced expiratory volume test (FEV1) is essentially the volume of air that can be blown out in the first second of exhaling. Another significant test is the forced vital capacity (FVC) test, which measures lung’s volume capacity. When measuring lung capacity, a common statistic is a combination of the two tests called the FEV1/FVC ratio.  This number essentially represents the percentage that the lungs can breathe out of the quantity of air inhaled. A healthy person has a FEV1/FVC ratio of or around 80 percent. Thus the lower the FEV1/FVC ratio the more significant the disease.

Stage Two COPD is categorized by a FEV1 test score that is greater than 50 percent but less than 80 percent and a FEV1/FVC ratio of less than 70 percent.

Stage Two COPD Symptoms:

  • Chronic coughing
  • Sputum: coughing up mucus
  • Dyspnea: breathing discomfort
  • Shortness of breath
  • Chest tightness

Stage Two COPD Treatment

Patients that seek medical assistance from a physician are occasionally prescribed ashort-acting bronchodilator and a long-acting bronchodilator to help increase airflow to the lungs . Given the major damage done by smoking with COPD, a smoking cessation  plan is always recommended. Likewise, it is also recommended to monitor environmental factors to keep dust, air pollution and other particles out of the lungs. Additionally, a pulmonary rehabilitation program may also be recommended.

If you would like to find out more about our available treatment options for COPD, please contact one of our patient care coordinators today at 888-745-6697 to schedule a free consultation.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.